Literature DB >> 8339658

Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis.

A Pollak1, R H Falk.   

Abstract

Cardiac amyloidosis produces a restrictive cardiomyopathy with impaired diastolic function. We report a case in which low-dose verapamil resulted in marked worsening of congestive heart failure, as a result of a profound negative inotropic effect. Withdrawal of verapamil therapy demonstrated a return of systolic function to normal with improvement in heart failure. We postulate that patients with cardiac amyloidosis may be exceptionally sensitive to the negative inotropic effects of calcium-channel blockers either because of abnormal binding to amyloid fibrils or because their usual vasodilator effects are blunted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339658     DOI: 10.1378/chest.104.2.618

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  27 in total

1.  Restrictive Cardiomyopathy.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10

Review 2.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

Review 3.  Advances in Treatment of Cardiac Amyloid.

Authors:  Cherie N Dahm; R Frank Cornell; Daniel J Lenihan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

Review 4.  Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.

Authors:  David C Seldin; John L Berk; Flora Sam; Vaishali Sanchorawala
Journal:  Heart Fail Clin       Date:  2011-05-20       Impact factor: 3.179

Review 5.  Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.

Authors:  Omar K Siddiqi; Frederick L Ruberg
Journal:  Trends Cardiovasc Med       Date:  2017-07-13       Impact factor: 6.677

Review 6.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

Review 7.  Cardiac amyloidosis: the heart of the matter.

Authors:  Federico Perfetto; Francesco Cappelli; Franco Bergesio; Gabriele Ciuti; Maria Cristina Porciani; Luigi Padeletti; Alberto Moggi Pignone
Journal:  Intern Emerg Med       Date:  2011-07-08       Impact factor: 3.397

Review 8.  Transthyretin Cardiac Amyloidosis in Black Americans.

Authors:  Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

Review 9.  Transthyretin Cardiac Amyloidosis.

Authors:  Anit K Mankad; Keyur B Shah
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

10.  Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease.

Authors:  Sandra Ihne; Caroline Morbach; Claudia Sommer; Andreas Geier; Stefan Knop; Stefan Störk
Journal:  Dtsch Arztebl Int       Date:  2020-03-06       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.